Monocyte HLA‐DRexpression as an enrollment biomarker in sepsis clinical trials: Evaluation of two sampling tubes and definition of respective clinical thresholds

MLA

Haem Rahimi, Muzhda, et al. “Monocyte HLA‐DRexpression as an Enrollment Biomarker in Sepsis Clinical Trials: Evaluation of Two Sampling Tubes and Definition of Respective Clinical Thresholds.” Cytometry Part B: Clinical Cytometry, vol. 104, no. 6, Nov. 2023, pp. 468–70. EBSCOhost, https://doi.org/10.1002/cyto.b.22133.

APA

Haem Rahimi, M., Conti, F., Llitjos, J., Fleurie, A., Cerro, V., Venet, F., Lukaszewicz, A., & Monneret, G. (2023). Monocyte HLA‐DRexpression as an enrollment biomarker in sepsis clinical trials: Evaluation of two sampling tubes and definition of respective clinical thresholds. Cytometry Part B: Clinical Cytometry, 104(6), 468–470. https://doi.org/10.1002/cyto.b.22133

Chicago

Haem Rahimi, Muzhda, Filippo Conti, Jean‐Francois Llitjos, Aurore Fleurie, Valérie Cerro, Fabienne Venet, Anne‐Claire Lukaszewicz, and Guillaume Monneret. 2023. “Monocyte HLA‐DRexpression as an Enrollment Biomarker in Sepsis Clinical Trials: Evaluation of Two Sampling Tubes and Definition of Respective Clinical Thresholds.” Cytometry Part B: Clinical Cytometry 104 (6): 468–70. doi:10.1002/cyto.b.22133.